UK Cystic Fibrosis Market Analysis

$3,500.00$7,500.00

  • Type: Rare Disease Area
  • Published : April 2021
  • Region: Europe
  • Country: UK
  • Report ID : 2568

  • Format: PPT, PDF

UK Cystic Fibrosis Therapeutics Market: Segmented by Antibiotics, Muco-Active Therapies, Bronchodilators and Steroids, Other Therapies, Route of Administration, and Distribution Channels – Size, Share, Impact, Growth, Trends, and Forecasts (2019 – 2028)

Published Date: June 2021

Clear
SKU: 2568 Categories: ,

Report Overview

The UK Cystic Fibrosis (CF) Therapeutics market size stood at around USD 0.020 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Cystic Fibrosis (CF) is an inherited disease caused by a faulty version of a gene known as ‘CFTR’. The gene and the protein help control the movement of salt and water in and out of cells. When the gene is faulty, it can cause thicker mucus, thus lungs the major affected body organ; over time this thick mucus blocks and damages airways, leading to infections and making it hard to breathe. People with CF may also develop other problems, such as liver disease or CF-related diabetes (CFRD). Around 85%of people with CF also have difficulty digesting food.

According to UK Cystic Fibrosis Registry, in 2019, around 10655 CF patients have registered; more than 60% of the population are aged 16 or over and 21 is the median age of the UK CF population. Around 30% of the patient are diagnosed by New-born Screening (NBS). Of the 114 people with CF who died in 2019, the median age at death was 31 years old.

Market Growth Drivers

The prevalence of Cystic Fibrosis (CF) is considered a major driving factor in the UK market as around 10655 CF patients have been registered in 2019. Thus, the rising prevalence of respiratory problems, GI complications, and reproductive disorders in patients with CF is also expected to boost the demand for the treatment of disease during the forecast period.

The emergence of drugs that are targeting the defect in cells of people suffering from CF is enhancing market growth during the forecast period. In addition to this, many potential candidates are in their final stages of development and are projecting the growth of the market in the near future. For instance, Vertex Pharmaceuticals Inc. announced positive results from their phase III clinical study on inhaled mannitol indicated for the treatment of mucociliary clearance.

Along with this, the increasing incidence of chronic cough, blood in sputum, & collapsed lungs, and the technologically advanced devices used for various serious cases such as airway clearance techniques, mucous thinners, and others also propelling the CF therapeutics market during the forecast period.

The sudden outbreak of the COVID-19 pandemic brings the patient is at high risk of being infected by the virus. This, coupled with other various complications such as lung infections, inflammation of the pancreas, CF-related diabetes, and others strongly augmenting the CF market growth during the forecast period.

TABLE OF CONTENTS

1. UK Cystic Fibrosis Therapeutics Market Overview………………………………
A. Market Size
2. Market Growth Drivers………………………………………………………………….
A. Rising Prevalence and Incidence of CF Propels the Market Growth
B. Emergence of Potential Drugs Boosts the Market Growth
C. Outbreak of COVID-19 Pandemic Augments the Market Growth
3. Major Causes of Cystic Fibrosis……………………………………
A. Infection caused by Pseudomonas aeruginosa
B. Infection caused by non-tuberculous mycobacterium (NTM)
C. Infection caused by Aspergillus
4. Cystic Fibrosis Therapeutics Market Segmentation…………………………….
A. By Antibiotics
I. Intravenous (IV) Antibiotics
II. Inhaled Antibiotics
III. Long-term Azithromycin use
IV. Prophylactic Flucloxacillin use
V. Others
B. By Muco-active Therapies
I. Mannitol
II. DNase
III. Hypertonic Saline
IV. Burden of Treatment
V. Others
C. By Bronchodilators and Steroids
I. Inhaled Bronchodilators
II. Inhaled Corticosteroids
III. Others
D. By Other Therapies
I. CFTR modifiers
II. Physiotherapy
III. Transplants
IV. Others
E. By Route of Administration
I. Oral
II. Parenteral
III. Others
F. By Distribution Channels
I. Retail Pharmacies
II. Hospitals Pharmacies
III. Online Pharmacies
IV. Drug Stores
V. Others
5. Cystic Fibrosis Major Drugs Market Share………………………………
A. Market Analysis, Insights and Forecast – By Revenue Type
6. Competitive Landscape…………………………………………………………………
A. Major Players
B. Products in Pipeline
7. Key Company Profiles………………………………………………………………….
A. Vertex Company overview, Product & Services, Strategies & Financials
B. Novartis Company overview, Product & Services, Strategies & Financials
C. GlaxoSmithKline Company, Product & Services, Strategies & Financials
D. Pfizer Company, Product & Services, Strategies & Financials
E. Gilead Sciences Company, Product & Services, Strategies & Financials
F. AbbVie Company, Product & Services, Strategies & Financials
G. Johnson & Johnson Company, Product & Services, Strategies & Financials
8. Healthcare Policies and Regulatory Landscape…………………………
A. Policy changes and Reimbursement scenario
9. Factors Driving Future Growth……………………………………………
A. New Trends and Development of Cystic Fibrosis Therapeutics Market
B. Future Opportunities
10. Conclusion

Market Segmentation

By Antibiotics:

On the basis of antibiotics, the cystic fibrosis treatment market has been categorized into

  • Intravenous (IV) Antibiotics
  • Inhaled Antibiotics
  • Long-term Azithromycin use
  • Prophylactic Flucloxacillin use
  • Others

IV antibiotics are given to the patient through their veins. This treatment can take a number of days and might take place as a hospital inpatient, or at home. The proportion of patients receiving at least one IV course at home was 23.1% and in-hospital was 38.0%. About 90% of people chronically infected with Pseudomonas aeruginosa should be prescribed at least one of the inhaled antibiotics (Colistin, Promixin, Aztreonam, Tobramycin). Azithromycin is an antibiotic with some anti-inflammatory properties. It is recommended for long-term use as a prophylactic antibiotic in people with chronic Pseudomonas aeruginosa.

By Muco-active Therapies:

In terms of muco-active therapies, the cystic fibrosis treatment market has been classified into

  • Mannitol
  • DNase
  • Hypertonic Saline
  • Burden of Treatment
  • Others

This treatment helps to thin mucus so that it is easier to cough out of the body. In the UK, about 36.8% of people are on hypertonic saline or mannitol. And 67.6% of people are on DNase.

By Bronchodilators and Steroids:

In terms of bronchodilators and steroids, the cystic fibrosis treatment market has been divided into

  • Inhaled Bronchodilators
  • Inhaled Corticosteroids
  • Others

Bronchodilators and corticosteroids targeted the beta-2 receptor, activates it, and relax the airway smooth muscles. In the UK, around 10655 CF patients have been registered, out of which around 60% patients solely on inhaled bronchodilators and the rest on inhaled cortico-steroids and the combination therapy.

By Other Therapies:

Based on other therapies, the cystic fibrosis treatment market has been classified into

  • CFTR modifiers
  • Physiotherapy
  • Transplants
  • Others

As of 2019, Ivacaftor was approved for use on the NHS across the UK for people aged one year and older with at least one copy of 9 specified CFTR ‘gating’ mutations, and for people aged 18 and over with the R117H mutation. In June 2020, the marketing authorization was extended to cover anyone aged 6 months and over with the R117H mutation. Lumacaftor/Ivacaftor is licensed for use in patients aged 2 years and over with two copies of the F508del mutation. Tezacaftor/Ivacaftor is licensed for use in patients aged 12 and over who have two copies of the F508del mutation, or a single copy of F508del and one of 14 specified ‘residual function’ mutations. Elexacaftor/Tezacaftor/Ivacaftor is accessible through a named patient access scheme to eligible individuals who are critically ill. 13 people with cystic fibrosis in the UK are recorded as having received Elexacaftor/Tezacaftor/Ivacaftor in 2019

By Route of Administration:

In terms of route of administration, the cystic fibrosis treatment market has been segmented into

  • Oral
  • Parenteral
  • Others

The parenteral route of administration which includes inhaled and injections holds the largest market share owing to the speedy recovery of cystic fibrosis. Also, the oral route of administration also fosters the cystic fibrosis market share; for example, the development of CFTR drugs.

By Distribution Channel:

Based on the distribution channel, the cystic fibrosis treatment market is classified into

  • Retail pharmacies
  • Drug stores
  • Hospital pharmacies
  • Online pharmacies
  • Others

Retail pharmacies and drug stores are anticipated to dominate the market. But due to the COVID-19 pandemic, online pharmacies boost up the market share as well and anticipated to emerge as the fastest-growing segment in the market. The convenience of drugs, easy availability, and others are augmenting the growth of online pharmacies during the forecast period.

Top Major Players

Major key players operating in UK Cystic Fibrosis (CF) markets are Vertex Pharmaceuticals Incorporated, AbbVie Inc., Novartis AG, Gilead Sciences Inc., Pfizer Inc., GlaxoSmithKline Plc., Johnson & Johnson, and others. Four branded drugs; Kaftrio (triple combination therapy), Symkevi, Kalydaco, and Orkambi currently marketed by Vertex Pharmaceuticals Incorporated are the best medication drugs trusted by over 90% of the patients affected by cystic fibrosis in the UK will foster the market share during the forecast period.

Research Methodology

Insights10 will provide you reports within 10 key parameters which are:

  1. Market overview
  2. Market growth drivers & restraints
  3. Epidemiology or disease type
  4. Market segmentation
  5. Market share
  6. Competitive landscape
  7. Key company profiles
  8. Healthcare policies & regulatory framework
  9. Reimbursement scenario
  10. Factors driving future growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision making for business stakeholders. Our focused approach to develop reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

Our analysis methodology involves three critical stages:

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers and researchers across countries through which we engage with local experts to gather key data points and assumptions around each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain the high level of accuracy and consistency. The market data is analysed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, market share as well as segment-level analysis of the specific market. Our report includes precise, to the point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

  • Statistical Databases
  • Company Websites/Annual Reports
  • Trade Publications
  • Online Databases
  • Published Research Reports
  • Whitepapers
  • Press Releases of Key Market Players

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameter and micro indicators. The macro parameters includes changes in government policies, demand and supply of the market, government intervention programs and major market share. The micro indicators GDP growth, market size, market volume etc. We also understand nuances specific to each country like US, Canada, India, Germany, etc. and have worked across 60+ countries and hence no only understand global trends, but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. start with large overall market and segment different areas and bottom-up approach i.e. start with population and epidemiology and roll up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach mainly used for new product forecasting and bottom-up approach is used for demand estimation of any product for different countries summed up to form total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and Africa for the period of 2020 to 2028. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape and policy and regulatory scenario and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases and the company level averages etc.

We make sure to finalize the numbers in alignment to the market research. Firstly, our internal experts ensure thorough validation and checking to ensure the accurate and precise analysis and then validation is also done using multiple data analysis model.  Two level validation is done and entails finalization of report scope and to way of representation pattern.

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analysed and synthesized. A second series of interviews are done if necessary to check and validate. The future opportunities are analysed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results are then, interpreted by considering following parameters: (a partial list)

  • Establishing market drivers and trends
  • Analyzing regulatory landscape to understand future growth
  • Market Segment based analysis to obtain revenue / volume
  • Analyzing current needs and determining penetration to estimate market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and its impact to the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumptions.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.

To request a free sample copy this report, please complete the form below.

    We value your inquiry and offer free customization with every report to fulfil your exact research needs.

    This website is secure and your personal details are safe.



    This report addresses

    • Market intelligence to enable effective decision making
    • Growth opportunities and trend analysis
    • Competitive benchmarking
    • Historical data & forecasts
    • Regional opportunities

    Need more?

    • Speak to our analyst to know how this research was put together
    • Add more countries or regions as part of customisation
    • Understand how this report can have direct impact on your revenue

    Get a custom report based on your requirements